Choline Sleep Randomized Trial: What the Evidence Says

Quick Answer

Choline Sleep Randomized Trial has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass are randomized trial, so conclusions should be framed as evidence-aware guidance rather than medical advice.

Key Takeaways

• This page is generated only from sources stored in the Migaku evidence knowledge base.
• Current evidence mix: 1 randomized trial, 1 narrative review.
• Claims should be interpreted with the source type, study design, population, and publication date in mind.
• This article is educational and does not replace care from a qualified clinician.

Evidence Map

What The Sources Report

• 7 8 9 10-12 13 14 Hyperlipidemia (HLP) refers to a systemic lipid metabolism abnormality characterized by elevated levels of total cholesterol (TC), triglycerides (TG), and/or low-density lipoprotein cholesterol (LDL-C), and/or reduced levels of high-density lipoprotein cholesterol (HDL-C) in the plasma due to various causes. [Xie Haihua (2026); evidence level 2]
• HLP, particularly elevated LDL-C levels, has been established as a risk factor for cardiovascular diseases and cognitive disorders (CD). [Xie Haihua (2026); evidence level 2]
• While intrinsic genetic factors drive much of this neurodevelopment, emerging evidence highlights the influence of extrinsic factors, particularly gut health, sleep architecture, and nutrition. [Chaturvedi Devyani (2026); evidence level 3]
• However, disruptions in this process may result from factors such as cesarean delivery, antibiotic exposure, early-life stress, or diets lacking key nutrients and probiotics that favorably modulate the gut microbiota, thereby directly impacting neurodevelopmental outcomes. [Chaturvedi Devyani (2026); evidence level 3]

How To Read This Evidence

Evidence level 1 generally reflects systematic reviews or meta-analyses. Level 2 includes randomized trials, guidelines, or public-health guidance. Level 3 usually reflects observational or narrative-review evidence. Level 4 is weaker or early-stage evidence. The level is a sorting aid, not a final quality grade.

Practical Interpretation

There is trial evidence in the current set, but population and intervention details still matter. For choline sleep randomized trial, the next editorial step is to add more targeted sources and separate strong findings from early or indirect evidence.

Limits Of This First Pass

This is a small-batch MVP article. It uses the first ingested sources for this topic and should be expanded with more targeted searches, license review, and human editorial checks before being treated as a definitive review.

References

• Xie Haihua (2026). Impact of infrared moxibustion for patients with mild hyperlipidemia: a protocol for a randomized controlled trial. DOI: 10.1080/07853890.2026.2665513. PMCID: PMC13148090. PMID: 42080526. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC13148090/
• Chaturvedi Devyani (2026). Interconnected Developmental Trajectories of the Brain, Gut, and Sleep in Early Life: The First 1000 Days of Nutritional Opportunity. DOI: 10.3390/nu18030445. PMCID: PMC12899498. PMID: 41683267. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC12899498/

Safety Note

Health information can change, and individual risk depends on medical history, medications, pregnancy status, age, and diagnosis. Talk with a qualified clinician before changing treatment, supplement, or medication routines.